Date of Award
2025
Document Type
Capstone
Degree Name
Master of Science (MS)
Committee Chair
Trey Boyd
Abstract
Introduction: Obesity is a growing chronic condition worldwide with limited effective and safe treatment options. Semaglutide and liraglutide are two GLP-1a medications with encouraging outcomes for the treatment of obesity. The purpose of this paper is to compare semaglutide to liraglutide for weight loss and obesity
Methods: Pubmed was searched for randomized controlled trials, systematic reviews, and meta- analyses from 2019 to 2024 to assess efficacy of semaglutide and liraglutide. Five articles were selected for clinical review.
Results: In 4 out of the 5 studies there was a greater reduction in weight in patients receiving semaglutide compared to liraglutide. Statistically significant improvements in HbA1c were noted in patients taking semaglutide. Most common adverse effects were gastrointestinal issues, which were noted with both semaglutide and liraglutide treatments.
Discussion: Studies suggest that semaglutide may be more effective in promoting weight loss as compared to liraglutide. Further research is needed to determine long-term effects of semaglutide for weight loss.
Recommended Citation
Bar, Orian, "Semaglutide vs Liraglutide for Weight Loss in Adults with Obesity" (2025). The PA Department Journal of Medical Science. 24.
https://digitalcommons.gardner-webb.edu/pa-department-journal-of-medical-science/24
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License